Zenoxa OD 900 Tablet SR contains Oxcarbazepine 900 mg as its active ingredient and is formulated as a sustained-release (SR) tablet to provide prolonged therapeutic effects. Oxcarbazepine is an anticonvulsant medication primarily indicated for the treatment of partial seizures in adults and children aged six years and above. It acts by stabilizing hyperexcited neural membranes, inhibiting repetitive neuronal firing, and reducing the propagation of seizure activity through modulation of voltage-sensitive sodium channels. The sustained-release formulation ensures a steady plasma concentration, enhancing patient compliance by allowing once-daily dosing and minimizing peak-related side effects. Zenoxa OD 900 Tablet SR is also utilized as adjunctive therapy in generalized tonic-clonic seizures and may be considered in certain cases of bipolar disorder. Common adverse effects include dizziness, somnolence, headache, nausea, and hyponatremia, necessitating periodic monitoring of serum sodium levels during therapy. Caution is advised in patients with a history of hypersensitivity to carbamazepine or oxcarbazepine, and gradual dose titration is recommended to mitigate central nervous system side effects. This medication should be prescribed and administered under medical supervision, with dose adjustments based on clinical response and tolerability. Zenoxa OD 900 Tablet SR represents an effective option for seizure management with a favorable safety profile when used appropriately.